Ketogenic Diet

This review explores the potential of ketogenic diets (KDs) and ketone supplementation (KS) in managing Alzheimer's disease (AD) and cognitive decline. KDs shift the brain’s energy source from glucose to ketones, reducing neuroinflammation, improving mitochondrial function, and supporting synaptic health. Animal studies demonstrate reduced amyloid and tau pathology, while human trials suggest improved cognition and memory, particularly in early AD stages. However, challenges include adherence, weight loss, and limited long-term research on safety and efficacy.

This study investigated the ketogenic diet's (KD) ability to stimulate autophagy in the brain, a process crucial for clearing cellular waste and maintaining brain health. Using mouse models, researchers found that KD increased autophagosome levels, particularly in the hippocampus and frontal cortex, suggesting enhanced brain cell repair and protection. This mechanism may explain KD's neuroprotective benefits in managing conditions like epilepsy and potentially slowing brain aging and neurodegeneration. These findings advance our understanding of KD's impact on brain health.

This review discusses the ketogenic diet's (KD) potential in reducing neuroinflammation and improving outcomes in neurodegenerative diseases like Alzheimer’s, Parkinson’s, ALS, and Huntington’s. KD shifts energy metabolism from glucose to ketones, reducing oxidative stress and promoting mitochondrial health. By modulating immune cell activity and decreasing inflammatory cytokines, KD shows promise in protecting neurons. Animal studies and limited clinical trials reveal cognitive and motor benefits, though long-term effects and patient adherence remain challenging.

This study investigated the effects of a cyclic ketogenic diet (KD) on aging mice. The diet, alternating weekly between KD and a regular diet, improved memory and reduced midlife mortality without increasing maximum lifespan. KD promoted neuroprotection by activating cellular pathways like PPARα, linked to energy metabolism and inflammation reduction. It preserved memory in tasks like novel object recognition and place avoidance, suggesting enhanced cognitive resilience. These findings indicate that KD can mimic fasting’s health benefits while preventing weight gain.

This study explored the effects of a ketogenic diet (KD) on cognitive dysfunction and neuroinflammation in a mouse model of Alzheimer’s disease (AD). The KD improved memory and learning, reduced amyloid-beta plaques (a hallmark of AD), and decreased neuroinflammatory markers. Mechanistically, the diet activated the Nrf2/HO-1 pathway, enhancing the brain’s antioxidant defenses, while suppressing the pro-inflammatory NF-κB signaling. These results suggest that the KD may mitigate neurodegeneration by addressing inflammation and oxidative stress, two key factors in AD progression.

This review examines the ketogenic diet (KD) as a potential therapy for Alzheimer’s disease (AD). KD promotes a shift from glucose to ketones as the brain's energy source, compensating for glucose metabolism impairments in AD. It reduces amyloid-beta plaques and tau tangles, decreases neuroinflammation, and enhances mitochondrial function, all of which are implicated in AD progression. Both preclinical and limited clinical studies indicate that KD may improve cognitive function and slow neurodegeneration, particularly in early stages of AD.

This paper explores how artificial intelligence (AI) can be used to personalize ketogenic diets (KD) to optimize brain health. AI-driven approaches account for individual differences in genetics, metabolism, and lifestyle to tailor macronutrient ratios and dietary adjustments. By enhancing ketone production, reducing inflammation, and improving mitochondrial function, personalized KDs have the potential to improve cognitive performance and protect against neurological diseases like Alzheimer's. AI applications like real-time biomarker tracking and microbiome analysis further refine this dietary intervention.

This randomized crossover trial assessed the effects of a 12-week modified ketogenic diet (KD) on Alzheimer’s disease (AD) patients. The KD improved daily function and quality of life significantly compared to a standard low-fat diet, though cognitive improvements were not statistically significant. Participants maintained a state of ketosis, supporting brain energy through ketones rather than glucose. Changes in cardiovascular markers were mostly positive, and adverse effects were mild, suggesting the diet is safe and feasible for managing AD symptoms.

This review examines the role of ketogenic diets (KDs) in managing Alzheimer’s and Parkinson’s diseases. By shifting energy metabolism to ketones, KD reduces oxidative stress, improves mitochondrial function, and decreases neuroinflammation, all contributing to better brain health. Evidence from animal studies and limited human trials shows KD can improve motor and cognitive symptoms, reduce amyloid-beta plaques in Alzheimer’s, and enhance dopamine production in Parkinson’s. However, adherence challenges and potential long-term risks require further investigation.

This review investigates the ketogenic diet (KD) in psychiatric conditions like anxiety, depression, bipolar disorder, schizophrenia, autism spectrum disorder (ASD), and ADHD. KD improves symptoms in animal models, showing reductions in anxiety and depression-like behaviors, mood stabilization, and decreased social deficits. However, human evidence is limited, mostly anecdotal or from small uncontrolled studies. Mechanisms involve enhanced energy metabolism, reduced neuroinflammation, and neurotransmitter regulation, but adherence and standardization pose challenges.

This scoping review discusses the ketogenic diet (KD) and its effects on neurodegenerative and psychiatric conditions such as Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, autism, and depression. KD promotes brain health by reducing inflammation, oxidative stress, and amyloid plaques while enhancing mitochondrial function, neuronal repair, and gut microbiome diversity. While basic research and animal studies show promising results, clinical evidence is limited due to small sample sizes, short durations, and lack of controls in human studies.

This review explores the ketogenic diet's (KD) potential in treating neurological diseases, including epilepsy, Alzheimer’s, Parkinson’s, multiple sclerosis, and migraine. KD induces ketosis, where ketones replace glucose as the brain's primary energy source, reducing inflammation, oxidative stress, and neuron damage. The diet also boosts mitochondrial function and supports nerve repair. While KD shows proven benefits for epilepsy, evidence for other conditions is promising but limited, often relying on animal studies and small human trials.

This systematic review analyzed randomized controlled trials (RCTs) investigating ketogenic therapies for Alzheimer’s disease (AD) and mild cognitive impairment (MCI). The review found that ketogenic diets or supplements, such as medium-chain triglycerides (MCTs), improved general cognition and memory over short- and long-term interventions. Ketone production enhanced brain energy metabolism, particularly in those without the APOE ε4 allele, while attention and executive function showed minimal changes. Despite promising findings, study designs were highly variable, requiring further standardization and research.